GTHX - G1 Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

G1 Therapeutics, Inc.

700 Park Offices Drive
Suite 200
Research Triangle Park, NC 27709
United States
919 213 9835
http://www.g1therapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees104

Key Executives

NameTitlePayExercisedYear Born
Dr. Mark A. VellecaCEO, Pres & Director878.21k175.68k1964
Ms. Jennifer K. MosesChief Financial Officer441.6k75.54k1975
Dr. Rajesh K. MalikChief Medical Officer and Sr. VP of R&D560.17k136.78k1959
Mr. Mark AvaglianoChief Bus. Officer559.74kN/A1976
Mr. Terry L. MurdockChief Operating OfficerN/AN/A1960
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

Corporate Governance

G1 Therapeutics, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.